ENDOMETRIOID OVARIAN CARCINOMA
Clinical trials for ENDOMETRIOID OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIOID OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIOID OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis early-phase study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. About 172 participants will receive differen…
Matched conditions: ENDOMETRIOID OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo targets tough ovarian cancer
Disease control Recruiting nowThis study tests if two drugs, senaparib and temozolomide, can shrink tumors in people with a certain type of ovarian cancer that has an ARID1A gene change. About 18 adults with recurrent or persistent clear cell or endometrioid ovarian, fallopian tube, or primary peritoneal canc…
Matched conditions: ENDOMETRIOID OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC